



Anika to Issue Fourth-Quarter 2017 Financial Results and Business Highlights on Wednesday, February 21

BEDFORD, Mass.--(BUSINESS WIRE)-- [Anika Therapeutics, Inc.](#) (NASDAQ: ANIK) today announced that the Company plans to issue its fourth-quarter 2017 financial results after the close of the market on Wednesday, February 21, 2017 and to hold a conference call the next day, Thursday, February 22, 2018, at 9:00 a.m. ET to discuss its financial results, business highlights, and outlook.

The conference call can be accessed by dialing 1-855-468-0611 (toll-free domestic) or 1-484-756-4332 (international). A live audio webcast will be available in the "[Investor Relations](#)" section of Anika's website, www.anikatherapeutics.com. An accompanying slide presentation also can be accessed via the Anika Therapeutics website. The call will be archived and accessible on the same website shortly after its conclusion.

About Anika Therapeutics, Inc.

[Anika Therapeutics, Inc.](#) (NASDAQ: ANIK) is a global, integrated orthopedic medicines company based in Bedford, Massachusetts. Anika is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies along the continuum of care, from palliative pain management to regenerative cartilage repair. The Company has over two decades of global expertise developing, manufacturing, and commercializing more than 20 products based on its proprietary [hyaluronic acid \(HA\) technology](#). Anika's orthopedic medicine portfolio includes [ORTHOVISC®](#), [MONOVISC®](#), and [CINGAL®](#), which alleviate pain and restore joint function by replenishing depleted HA, and [HYALOFAST®](#), a solid HA-based scaffold to aid cartilage repair and regeneration. For more information about Anika, please visit www.anikatherapeutics.com.

▪

View source version on [businesswire.com](http://www.businesswire.com): <http://www.businesswire.com/news/home/20180207005986/en/>

For Investor Inquiries:

Sylvia Cheung, Chief Financial Officer

Anika Therapeutics, Inc.

Tel: 781.457.9000

or

For Media Inquiries:

Sonal Vasudev

Pure Communications

Tel: 917.523.1418, sonal@w2ogroup.com

Source: Anika Therapeutics, Inc.

News Provided by Acquire Media
